Solidus Investment

Dr.Diary is a company that provides a comprehensive diabetes management application aimed at helping users monitor and manage their condition effectively. Founded in 2017 and based in Seoul, South Korea, the application allows users to track their blood glucose levels, exercise routines, and food intake, while offering insights on how these factors influence their health. In addition to these features, the platform includes medicine intake reminders, monthly health reports, and daily tips on diabetes management. It also facilitates communication with friends and provides personal consultation services with healthcare professionals, enhancing the overall user experience in managing diabetes.

Ubix Therapeutics, Inc. is a research and development company based in Seoul, South Korea, focused on creating anti-cancer drugs through its innovative proteolysis targeting chimera platform technology. This approach employs inhibitor technology to degrade specific target proteins within cells, aiming to enhance therapeutic efficacy for various cancers. By binding to proteins associated with targeted diseases, Ubix Therapeutics seeks to provide effective and life-saving treatments for patients, thereby supporting medical professionals in their efforts to combat cancer.

Mepsgen is a biotechnology research organization that focuses on pharmaceutical services and drug development.

Novelty Nobility Inc. is a private biotech company. They are currently focused on the research of novel angiogenesis targets and develop antibody-based therapeutics in ophthalmology and oncology, where angiogenesis plays a key pathogenic role. In ophthalmology, Novelty Nobility first discovered a novel angiogenesis target, Stem Cell Factor(SCF) and c-KIT, which was initially known for its engagement with proliferation and survival of primitive hematopoietic stem cells for a couple of past decades. We believe that anti-SCF/c-KIT could effectively address the unmet medical needs, mostly caused by inherent limitations of anti-VEGFs, in terms of treatment efficacy and long-term safety. Our target discovery is widely and strongly patent-protected in US/KOR and the lead pipeline, NN2101(a full-human monoclonal antibody), is currently under preclinical development.

Neurophet, Inc. is a neuroscience company based in Seoul, South Korea, founded in 2016. It specializes in developing innovative software solutions for brain stimulation and treatment of neurological disorders. The company's flagship product, Neurophet tES Lab, is a simulation software that calculates and visualizes the effects of brain stimulation by utilizing individual brain structures and specific stimulation conditions. Neurophet employs its proprietary Segengine technology, which can automatically segment brain magnetic resonance images into 107 distinct regions within a minute. This technology aids in predicting and investigating stimulation effects for conditions such as Alzheimer's disease, providing clinicians with a three-dimensional brain model and stimulation parameter guidance. By leveraging deep learning and numerical optimization techniques, Neurophet enables healthcare professionals to focus interventions on targeted regions of the brain, enhancing treatment efficacy for patients with brain diseases.

Onnuri Store sells household goods, beauty, health, and food products.

Dot Mill is a mixed reality content production company.

Healthbiome is a company that researches and develops microbiome-based treatment.

GB SOFT Co., Ltd. specializes in non-contact measurement solutions for bio-signals, including pulse, blood pressure, oxygen saturation, and heart rate variability. These bio-signals facilitate basic health assessments for daily living and medical environments. By analyzing these signals, the company can provide insights into fatigue, drowsiness, stress levels, and blood sugar. The measurement process is completed in under ten seconds with high accuracy, making it applicable across various sectors, such as automotive, transportation, construction, manufacturing, and well-being. Additionally, GB SOFT offers a safety management platform that enables clients to monitor bio-signals and manage time and attendance, enhancing workplace efficiency and safety through non-contact technology. The company's aim is to create a world where convenient, non-contact bio-signal measurement is accessible to everyone.

M2S specializes in creating digital contents of VR and AR.

Jocoos is a company focused on creating engaging platforms that empower individuals to share their talents and pursue their aspirations. Its flagship product, SURT, is a mobile application designed specifically for artists and musicians, enabling them to showcase their skills and connect with agencies, recording companies, producers, and fans. Additionally, Jocoos has developed cloud-based video technology that facilitates live streaming for various business applications. This technology includes a transcoder and live-streaming capabilities, along with a video editing tool that allows users to incorporate multimedia files, enhancing their ability to produce and share enjoyable live video content. Through these innovations, Jocoos aims to inspire creativity and connection among users.

Pharos iBio Co. is a biotechnology company focused on the development of innovative treatments for rare and intractable diseases. Leveraging a novel drug development platform that incorporates big data and artificial intelligence technology, the company aims to address significant medical needs. Among its product candidates are PHI-101-AML, targeting refractory or relapsed acute myeloid leukemia; PHI-101-OC, designed for patients with platinum-resistant or refractory ovarian cancer; and PHI-101-TNBC, aimed at treating metastatic triple-negative breast cancer. Additionally, the company is advancing several other candidates, including PHI-201, PHI-301, and PHI-501. Through its targeted approach, Pharos iBio seeks to contribute to the advancement of treatment options in oncology.

Himedi, Inc. is a digital health platform based in Seoul, South Korea, founded in 2011. The company connects international patients with medical service providers in South Korea, facilitating access to healthcare services. Himedi offers a hospital reservation service and provides consultations with doctors, while also recommending clinics suited to the patients' needs. Additionally, service managers accompany clients throughout their medical journeys, ensuring a seamless experience. This approach aims to enhance the quality of life for medical tourists by offering tailored healthcare solutions and support during their stay.

Market Designers is a company focused on transforming the brick-and-mortar market by leveraging online innovation to create new business opportunities. The company is developing various housing-related services, including running and cleaning, while also innovating market structures through advanced technology tailored to specific market characteristics. Their on-demand matching platform connects service providers with customers by utilizing algorithms to effectively align consumer needs with available services across sectors such as professional moving, cleaning, mortgage, and education. This approach enhances visibility for service providers and helps them expand their client base.

Orum Therapeutics is a private biotechnology company based in Daejeon, South Korea, founded in 2016. The company specializes in the research and development of therapeutic antibodies through its innovative cell-penetrating antibody platform, Oromab™. This platform is designed to target cytosolic proteins, addressing unmet medical needs in cancer and rare genetic diseases. Orum's unique approach allows for the intracellular delivery of active antibody therapeutics or payloads, enabling the inhibition of drug targets that have been previously considered undruggable by conventional small molecules or antibody therapies. Orum's technology is adaptable to various cell types and intracellular proteins without requiring chemical modifications, aiming to develop effective treatments with improved specificity and reduced toxicity.

Orum Therapeutics is a private biotechnology company based in Daejeon, South Korea, founded in 2016. The company specializes in the research and development of therapeutic antibodies through its innovative cell-penetrating antibody platform, Oromab™. This platform is designed to target cytosolic proteins, addressing unmet medical needs in cancer and rare genetic diseases. Orum's unique approach allows for the intracellular delivery of active antibody therapeutics or payloads, enabling the inhibition of drug targets that have been previously considered undruggable by conventional small molecules or antibody therapies. Orum's technology is adaptable to various cell types and intracellular proteins without requiring chemical modifications, aiming to develop effective treatments with improved specificity and reduced toxicity.

essys is a Manufacturing and sales of automotive IT parts.

Anygen Co., Ltd. is a bio-venture company based in Gwangju and Jeonnam province, established in 2000. It specializes in the development of peptide biomaterials and quality management technologies. The company manufactures a variety of peptide active pharmaceutical ingredients (APIs), including GMP, generic, custom, and catalog peptides. In 2016, Anygen was listed on the KOSDAQ market, bolstered by its proprietary peptide biomaterials and innovative drug development technologies. The company is recognized for supplying high-quality peptide medicinal materials, being the first in Korea to achieve GMP approval. By providing competitively priced peptide drug raw materials, Anygen aims to stabilize market prices and contribute to public health initiatives while expanding its presence in the global market.

Techcross specializes in the manufacturing of ballast water management systems aimed at protecting the marine environment. The company's innovative systems employ electrolysis technologies to prevent pollution from ship ballast water, addressing the ecological challenges posed by invasive marine species. These systems are designed for use on large vessels, including tankers and container ships, allowing companies to effectively treat ballast water in compliance with international environmental regulations. Through its focus on sustainable maritime practices, Techcross plays a crucial role in safeguarding marine ecosystems globally.

Purunagun Distribution is a Manufacture and distribution of ice cream with domestic agricultural products.

Cheongwoo Food is a Comprehensive Confectionery.

Genomictree, Inc. is a molecular diagnostics company focused on developing epigenomic biomarker-based technologies. The company aims to address unmet needs in the healthcare market by providing innovative diagnostic solutions. Through its research and development efforts, Genomictree seeks to enhance patient care and improve health outcomes by leveraging advanced molecular diagnostic tools.

Alteogen Inc. is a biopharmaceutical company founded in 2008 and based in Daejeon, South Korea. The company specializes in developing next-generation biobetters, antibody-drug conjugates, and antibody biosimilars. Its portfolio includes several innovative products, such as ALT-P1, a long-acting human growth hormone currently in Phase IIa clinical trials, and ALT-Q2, a long-acting coagulation factor VII for hemophilia treatment based on NexP technology. Additionally, Alteogen is developing ALT-P7, a targeted treatment for breast and gastric cancer in Phase I trials, and ALT-Q5, an antibody-drug conjugate for ovarian cancer utilizing NexMab technology. The company has established strategic alliances with Kissei Pharmaceutical for Aflibercept, which has completed pre-clinical trials, and with Cristalia for Trastuzumab, currently in Phase II trials for breast cancer. Through these efforts, Alteogen aims to enhance the efficacy and accessibility of biopharmaceuticals.

Novarex Co., Ltd. is a South Korean company specializing in the development and production of health functional foods and raw materials, both domestically and internationally. Founded in 2008 and headquartered in Cheongju, the company offers a diverse range of dietary supplements, including lactic acid bacteria, probiotics, omega-3 products, and vitamins. Novarex also provides health products tailored for specific needs, such as eye health, dietary support, and maternal and children's nutrition. The product formats include tablets, hard capsules, powders, gumi jellies, and stick jellies. Originally known as Health Science Co., Ltd., the company rebranded to Novarex in November 2011.

IDAL SYSTEM is a Smart RPC Management System.

Kookdae F & B is a franchise business.

BioLeaders Corporation is a healthcare company based in Yongin, South Korea, founded in 1999. The company focuses on developing innovative medicines, particularly in the field of oncology, with its flagship product being P53, an anti-cancer drug. BioLeaders is advancing several pipeline products, including BLS-H01, currently in phase 3 clinical trials for cervical cancer, and BLS-M07, which has completed phase 2b trials for the same condition. Additionally, the company is working on BLS-M22 for the treatment of Duchenne muscular dystrophy and BLC-H03, a vaccine adjuvant. Beyond pharmaceuticals, BioLeaders also offers health functional foods, raw materials, and functional cosmetic ingredients, positioning itself as a comprehensive provider in the healthcare sector.

Maniker F&G Co., Ltd. is a South Korean company that specializes in the production, processing, and sale of frozen, chilled, and retorted food products. Established in 1993 and headquartered in Yongin, the company offers a variety of chicken and beef items, including Ginseng chicken stew, Mung bean chicken stew, Premium Samgyetang, boneless chicken tenders, and popcorn chicken. Maniker F&G is committed to delivering safe and delicious food products through advanced meat processing technology. The company also exports its offerings to the United States, aiming to enhance customer health and convenience through continuous innovation and improvement.